2f2c: Difference between revisions

From Proteopedia
Jump to navigationJump to search
OCA (talk | contribs)
New page: left|200px<br /> <applet load="2f2c" size="450" color="white" frame="true" align="right" spinBox="true" caption="2f2c, resolution 2.80Å" /> '''X-ray structure of ...
 
OCA (talk | contribs)
No edit summary
Line 1: Line 1:
[[Image:2f2c.gif|left|200px]]<br />
[[Image:2f2c.gif|left|200px]]<br /><applet load="2f2c" size="350" color="white" frame="true" align="right" spinBox="true"  
<applet load="2f2c" size="450" color="white" frame="true" align="right" spinBox="true"  
caption="2f2c, resolution 2.80&Aring;" />
caption="2f2c, resolution 2.80&Aring;" />
'''X-ray structure of human CDK6-Vcyclinwith the inhibitor aminopurvalanol'''<br />
'''X-ray structure of human CDK6-Vcyclinwith the inhibitor aminopurvalanol'''<br />


==Overview==
==Overview==
Cyclin-dependent kinases (CDKs) are key players in cell cycle control, and, genetic alterations of CDKs and their regulators have been linked to a, variety of cancers. Hence, CDKs are obvious targets for therapeutic, intervention in various proliferative diseases, including cancer. To date, drug design efforts have mostly focused on CDK2 because methods for, crystallization of its inhibitor complexes have been well established., CDK4 and CDK6, however, may be at least as important as enzymes for cell, cycle regulation and could provide alternative treatment options. We, describe here two complex structures of human CDK6 with a very specific, kinase inhibitor, PD0332991, which is based on a, pyrido[2,3-d]pyrimidin-7-one scaffold, and with the less specific, aminopurvalanol inhibitor. Analysis of the structures suggests that, relatively small conformational differences between CDK2 and CDK6 in the, hinge region are contributing to the inhibitor specificity by inducing, changes in the inhibitor orientation that lead to sterical clashes in CDK2, but not CDK6. These complex structures provide valuable insights for the, future development of CDK-specific inhibitors.
Cyclin-dependent kinases (CDKs) are key players in cell cycle control, and genetic alterations of CDKs and their regulators have been linked to a variety of cancers. Hence, CDKs are obvious targets for therapeutic intervention in various proliferative diseases, including cancer. To date, drug design efforts have mostly focused on CDK2 because methods for crystallization of its inhibitor complexes have been well established. CDK4 and CDK6, however, may be at least as important as enzymes for cell cycle regulation and could provide alternative treatment options. We describe here two complex structures of human CDK6 with a very specific kinase inhibitor, PD0332991, which is based on a pyrido[2,3-d]pyrimidin-7-one scaffold, and with the less specific aminopurvalanol inhibitor. Analysis of the structures suggests that relatively small conformational differences between CDK2 and CDK6 in the hinge region are contributing to the inhibitor specificity by inducing changes in the inhibitor orientation that lead to sterical clashes in CDK2 but not CDK6. These complex structures provide valuable insights for the future development of CDK-specific inhibitors.


==About this Structure==
==About this Structure==
2F2C is a [http://en.wikipedia.org/wiki/Protein_complex Protein complex] structure of sequences from [http://en.wikipedia.org/wiki/Homo_sapiens Homo sapiens] and [http://en.wikipedia.org/wiki/Saimiriine_herpesvirus_2 Saimiriine herpesvirus 2] with SO4, AP9 and DMS as [http://en.wikipedia.org/wiki/ligands ligands]. Active as [http://en.wikipedia.org/wiki/Non-specific_serine/threonine_protein_kinase Non-specific serine/threonine protein kinase], with EC number [http://www.brenda-enzymes.info/php/result_flat.php4?ecno=2.7.11.1 2.7.11.1] Full crystallographic information is available from [http://ispc.weizmann.ac.il/oca-bin/ocashort?id=2F2C OCA].  
2F2C is a [http://en.wikipedia.org/wiki/Protein_complex Protein complex] structure of sequences from [http://en.wikipedia.org/wiki/Homo_sapiens Homo sapiens] and [http://en.wikipedia.org/wiki/Saimiriine_herpesvirus_2 Saimiriine herpesvirus 2] with <scene name='pdbligand=SO4:'>SO4</scene>, <scene name='pdbligand=AP9:'>AP9</scene> and <scene name='pdbligand=DMS:'>DMS</scene> as [http://en.wikipedia.org/wiki/ligands ligands]. Active as [http://en.wikipedia.org/wiki/Non-specific_serine/threonine_protein_kinase Non-specific serine/threonine protein kinase], with EC number [http://www.brenda-enzymes.info/php/result_flat.php4?ecno=2.7.11.1 2.7.11.1] Full crystallographic information is available from [http://oca.weizmann.ac.il/oca-bin/ocashort?id=2F2C OCA].  


==Reference==
==Reference==
Line 23: Line 22:
[[Category: small molecule inhibitor bound between n-terminal and c-terminal domain of kinase]]
[[Category: small molecule inhibitor bound between n-terminal and c-terminal domain of kinase]]


''Page seeded by [http://ispc.weizmann.ac.il/oca OCA ] on Mon Nov 12 21:58:53 2007''
''Page seeded by [http://oca.weizmann.ac.il/oca OCA ] on Thu Feb 21 17:16:59 2008''